Tumour Mutational Burden (TMB) — what a high score means

Tumour Mutational Burden counts the number of somatic mutations — changes in the DNA sequence that arose only in the tumour, not inherited from a parent — across a defined stretch of the genome, then expresses that count as mutations per megabase (mut/Mb). Historically this was calculated using whole-exome sequencing (WES), which reads essentially every protein-coding gene. Most clinical labs today estimate TMB from a large next-generation sequencing (NGS) panel covering several hundred genes, which correlates well with whole-exome results once properly calibrated.

The biological logic is straightforward: more mutations generally means more abnormal proteins, or neoantigens, sitting on the tumour's surface. A higher neoantigen load can make a tumour more visible to the immune system, which is part of why TMB is studied as a biomarker for how a tumour might respond to immune checkpoint inhibitors. TMB is not a measure of how advanced or aggressive a cancer is — a high-TMB tumour is not automatically a more dangerous one, and a low-TMB tumour is not automatically a milder one.

TMB testing itself is coordinated through CION's accredited partner molecular pathology and genomic-testing laboratories — the sequencing and bioinformatics analysis is a specialist laboratory process, not something performed in-house at a consultation.

Ranges shown are commonly cited reference bands from published companion-diagnostic labelling and NCCN/ASCO literature, indicative as of August 2026. Your oncologist confirms which cut-off applies to your specific test and treatment plan — this table is for general education, not an eligibility guarantee.

1. 1

   A tissue or blood sample is sequenced

   Usually a tumour block from an existing biopsy or surgical specimen is run through a next-generation sequencing panel; some labs also offer blood-based (liquid biopsy) TMB, though standardisation there is less mature.

2. 2

   Somatic mutations are identified

   Bioinformatics software compares the tumour DNA sequence against a reference and against your own normal DNA where available, filtering out inherited (germline) variants to isolate mutations that arose only in the tumour.

3. 3

   The count is normalised per megabase

   The total number of qualifying mutations is divided by the number of megabases of DNA the assay actually covers, producing the mut/Mb figure — this is why panel size directly affects the reported number.

4. 4

   The report reaches your oncology team

   The mut/Mb value, along with the assay used, is entered on your genomic report and reviewed against the relevant reference range for your cancer type and the treatment being considered.

• TMB result — one input, and it meets a formal treatment threshold only together with your cancer type, stage and prior treatment history for certain regulatory pathways.
• PD-L1 expression — measured separately by a different test (immunohistochemistry) and can support eligibility independently of TMB.
• MSI/dMMR status — a related but distinct biomarker; some high-TMB tumours are also MSI-High, but the two do not always overlap.
• Cancer type and approval pathway — the tumour-agnostic route that uses a TMB-High cut-off applies to specific, defined circumstances, not to every cancer or every drug.
• Overall fitness and prior treatment — general health, organ function and treatment history are part of any eligibility discussion.

A high TMB result does not guarantee a response to immunotherapy, and a low or intermediate result does not rule it out — it is one data point your tumour board reviews alongside everything else in your file.

TMB is not measured by one standardised test — it is generated by a family of next-generation sequencing panels that differ in how many genes they cover, which bioinformatics pipeline they use to call and filter mutations, and how large a "megabase" denominator they divide by. Two accredited labs testing the same tumour can occasionally report a modestly different mut/Mb figure as a result. For a broader look at how different testing methods compare, see our guide on IHC, NGS and liquid biopsy testing.

Groups such as the Friends of Cancer Research TMB Harmonization Project have worked to align reporting across platforms, but full standardisation is still evolving — a recognised, openly discussed limitation, not a sign of a testing error. TMB is generated from the same NGS run that produces other genomic markers, so it typically arrives on the same timeline; see how long biomarker results take, and why the wait for what to expect.

• IHC, NGS and Liquid Biopsy: Which Test Is Which? — how the testing method behind your TMB, PD-L1 or MSI result actually works.
• How Long Do Biomarker Results Take, and Why the Wait? — what a typical NGS-based reporting timeline looks like.
• Not Enough Tissue for Testing: What Happens Next — what your options are if your existing sample isn't sufficient for a TMB panel.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through the immunotherapy decision and journey.

This page explains general TMB terminology for education only and does not interpret any individual patient's report. TMB testing is coordinated at accredited partner molecular pathology laboratories. Bring your report to a consultation for a doctor's assessment of what it means for you.

Thousands of families have decoded their reports with us

A genomic report can feel like it holds your whole future in a few numbers. Our oncologists take the time to explain what yours actually means, in plain language.